secwatch.observer — SEC 8-K summary
======================================

Issuer:     AETHLON MEDICAL INC (AEMD)
CIK:        0000882291
Form:       8-K
Filed at:   2023-06-28T23:59:59+00:00
Accession:  0001683168-23-004477
Event type: earnings
Sentiment:  neutral
Materiality: 0.50
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Aethlon Medical reports FY2023 cash $14.5M, operating expenses $12.47M; advances Hemopurifier trials
--------------------------------------------------------------------------------

- Cash balance $14.5M at March 31, 2023; operating expenses $12.47M, up $1.76M from $10.71M in FY2022.
- COVID-19 ICU trial in India: one patient treated; second hospital (MAMC) got ethics approval in May 2023.
- Oncology clinical trial planned in Australia: safety/feasibility/dose-finding in solid tumors failing anti-PD-1 antibodies.
- New organ transplant initiative: testing Hemopurifier in machine perfusion to remove viruses/exosomes from harvested organs.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/882291/000168316823004477/0001683168-23-004477-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/882291/000168316823004477/aethlon_8k.htm
  HTML page:      https://secwatch.observer/filing/0001683168-23-004477

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer